Who should not take hormone therapy?
Direct Answer
Hormone therapy is generally avoided for women with a history of breast or endometrial cancer, active liver disease, unexplained vaginal bleeding, or a history of blood clots, stroke, or heart attack. A personal history of these conditions typically makes the risks of systemic HRT outweigh the benefits.
Detailed Explanation
While hormone therapy (HT) is a safe and highly effective option for the majority of women, it is not a "one-size-fits-all" treatment. There are specific medical conditions, known as contraindications, where the risks of systemic hormones may outweigh the benefits. Identifying these groups is a critical step in the clinical consultation process to ensure that every woman receives the most appropriate and safest care for her specific health profile.
The most significant absolute contraindication is a personal history of hormone-sensitive cancers, most notably breast cancer. Because estrogen can stimulate the growth of certain types of breast cancer cells, systemic HT (which raises hormone levels throughout the entire body) is generally avoided for survivors. Similarly, a history of endometrial (uterine) cancer is typically a contraindication, as estrogen can cause the lining of the uterus to thicken, potentially increasing the risk of recurrence. While there are rare exceptions made for women with severe, intractable symptoms after a thorough multi-disciplinary review, the standard of care remains non-hormonal management for these groups.
Cardiovascular health and clotting history are the other primary areas of concern. Systemic HT is generally not recommended for women who have had a stroke, a heart attack, or a history of deep vein thrombosis (DVT) or pulmonary embolism. This caution is primarily based on the fact that oral estrogen can increase the production of clotting factors in the liver. While transdermal estrogen (delivered via patches or gels) has been shown to have a much lower risk of clotting, it is still typically avoided in women with a strong personal history of these events. Active liver disease is also a contraindication, as the liver is responsible for processing hormones; however, transdermal options may be considered in some cases because they bypass the liver's "first-pass" metabolism.
Unexplained vaginal bleeding is an absolute contraindication that must be resolved before any hormone therapy can begin. Such bleeding can be a sign of endometrial hyperplasia (thickening of the uterine lining) or even uterine cancer. A healthcare provider must perform a thorough investigation, often including an ultrasound or biopsy, to ensure the uterus is healthy before adding supplemental hormones.
It is crucial to distinguish between systemic HT and local vaginal estrogen. Local estrogen, used to treat the Genitourinary Syndrome of Menopause (GSM), which includes vaginal dryness and urinary frequency, has very minimal systemic absorption. Because the levels of estrogen in the bloodstream remain extremely low, many women who cannot take systemic HT—including many breast cancer survivors—are still candidates for local vaginal estrogen. This allows them to treat debilitating local symptoms without significantly increasing their systemic cancer or clotting risk.
There are also "relative contraindications," where the decision to use HT depends on the specific formulation and the patient's overall health. For example, women with migraine with aura have a higher baseline risk of stroke, and oral estrogen can further increase that risk. However, many specialists consider low-dose transdermal estrogen to be a safe option for these women, as it provides stable hormone levels without the "spikes" associated with pills. Other relative contraindications include gallbladder disease and certain types of endometriosis, where the choice of progesterone and delivery method becomes paramount.
For women who fall into these contraindication groups, the good news is that there are now more non-hormonal options than ever before. These include lifestyle modifications, cognitive behavioral therapy for insomnia (CBT-I), and non-hormonal medications like SSRIs/SNRIs or the newly FDA-approved NK3 receptor antagonists (such as Fezolinetant), which specifically target the brain's "hot flash switch" without using hormones.
In summary, while the list of women who should not take systemic hormone therapy is relatively small, it is a vital list. A thorough medical screening allows healthcare providers to identify these risks and work with each woman to find the safest and most effective path for managing her menopause transition, whether that involves hormones or evidence-based alternatives.
Evidence Context
Contraindications are based on established safety data from clinical trials and observational studies. We distinguish between "absolute contraindications" (where the risk is clear) and "relative contraindications" (where the decision depends on the specific formulation and the patient's overall health profile).